umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Frontiers in Neurology, ISSN 1664-2295, E-ISSN 1664-2295, Vol. 6, artikel-id UNSP 18Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IVTYNERGY study, relapsing remitting MS patients showed a clinically meaningful decrease in fatigue over 1 year of treatment with natalizumab. Objective: To evaluate whether fatigue improvement might be directly linked to improved depression and day-time sleepiness. Methods: Patients were assessed regarding fatigue, depression, and day-time sleepiness. The relation between changes of the two latter symptoms and changes in fatigue was analyzed. Results: After 1 year of natalizumab treatment, the majority of patients (>92%) remained stable or improved in total, motor, and cognitive fatigue. Proportion of patients without depression increased by 17% while proportions of mildly depressed patients or patients with potential major depression decreased by 5 and 12%, respectively. Proportion of patients classified as not being sleepy increased by 13% while proportions of sleepy and very sleepy patients decreased by 11 and 2%, respectively. Most importantly, improved depression and sleepiness were significantly related to improved fatigue. Conclusion: Our findings highlight the importance of patient-reported outcomes in identifying potential benefits of drug treatment beyond its well-established effects on disease activity and disability progression.

Ort, förlag, år, upplaga, sidor
2015. Vol. 6, artikel-id UNSP 18
Nyckelord [en]
fatigue, multiple sclerosis, treatment response, depression, sleepiness
Nationell ämneskategori
Neurovetenskaper
Identifikatorer
URN: urn:nbn:se:umu:diva-111773DOI: 10.3389/fneur.2015.00018ISI: 000363764700001PubMedID: 25755648Scopus ID: 2-s2.0-84926286469OAI: oai:DiVA.org:umu-111773DiVA, id: diva2:873224
Tillgänglig från: 2015-11-23 Skapad: 2015-11-23 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

fulltext(1579 kB)232 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1579 kBChecksumma SHA-512
a5fd9f2422c0e0e2c6ffdc630547b2324cae1d3d7ead08645088a536fb251b85250d7b23c9bea1f108007a7c244910045ce3cdf65a21e44dcc132109f7e269da
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Svenningsson, Anders

Sök vidare i DiVA

Av författaren/redaktören
Svenningsson, Anders
Av organisationen
Klinisk neurovetenskap
I samma tidskrift
Frontiers in Neurology
Neurovetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 232 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 130 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf